Publication Name	World Journal of Gastroenterology
Manuscript ID	63631
Country	United States

Received	2021-03-22 02:38
Peer-Review Started	2021-03-22 02:42
To Make the First Decision
Return for Revision	2021-06-14 03:36
Revised	2021-07-28 20:04
Second Decision	2021-12-07 03:16
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-12-08 05:56
Articles in Press	2021-12-08 05:56
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-12-15 02:05
Publish the Manuscript Online	2021-12-17 08:56

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
Manuscript Source	Invited Manuscript
All Author List	Ajalaya Teyateeti, Armeen Mahvash, James Long, Mohamed Abdelsalam, Rony Avritscher, Ahmed Kaseb, Bruno Odisio, Gregory Ravizzini, Devaki Surasi, Achiraya Teyateeti, Homer Macapinlac and Srinivas Cheenu Kappadath
ORCID	Author(s) ORCID Number Ajalaya Teyateeti http://orcid.org/0000-0001-9778-0223 Armeen Mahvash http://orcid.org/0000-0003-0416-4566 James Long http://orcid.org/0000-0001-5853-5938 Mohamed Abdelsalam http://orcid.org/0000-0003-1066-2641 Rony Avritscher http://orcid.org/0000-0002-5122-3445 Ahmed Kaseb http://orcid.org/0000-0002-9491-0587 Bruno Odisio http://orcid.org/0000-0002-1771-8233 Gregory Ravizzini http://orcid.org/0000-0002-4659-5180 Devaki Surasi http://orcid.org/0000-0003-3174-1138 Achiraya Teyateeti http://orcid.org/0000-0001-5421-4248 Homer Macapinlac http://orcid.org/0000-0001-5781-5989 Srinivas Cheenu Kappadath http://orcid.org/0000-0003-4643-7745
Funding Agency and Grant Number
Corresponding Author	Srinivas Cheenu Kappadath, PhD, Associate Professor, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Unit 1352, Houston, TX 77030, United States. skappadath@mdanderson.org
Key Words	Radioembolization; Selective internal radiotherapy; Tumor response; Pattern of progression; Time to progression; Sorafenib
Core Tip	Hepatocellular carcinoma (HCC) patients treated with yttrium-90 transarterial radioembolization (TARE) alone for intrahepatic tumor load ≤ 50% and TARE with sorafenib for intrahepatic tumor load > 50% and/or present macrovascular invasion, extrahepatic disease or infiltrative HCC yielded acceptable disease control rates of 79.4% and 71.6%, respectively. Between these 2 subgroups, incidence of intrahepatic progression was comparable (about 40%) but extrahepatic progression was much less common with TARE alone (12.7% vs 32%). Strategies that improve intrahepatic control for liver-only disease (dosimetry-based TARE) and extrahepatic control for metastatic disease (additional systemic therapy) could improve TARE outcome for unresectable HCC patients.
Publish Date	2021-12-17 08:56
Citation	Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 2021; 27(47): 8166-8181
URL	https://www.wjgnet.com/1007-9327/full/v27/i47/8166.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i47.8166

Full Article (PDF)	WJG-27-8166.pdf
Full Article (Word)	WJG-27-8166.docx
Manuscript File	63631_Auto_Edited-YJM.docx
Answering Reviewers	63631-Answering reviewers.pdf
Audio Core Tip	63631-Audio core tip.mp3
Biostatistics Review Certificate	63631-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	63631-Conflict-of-interest statement.pdf
Copyright License Agreement	63631-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	63631-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	63631-Institutional review board statement.pdf
Peer-review Report	63631-Peer-review(s).pdf
Scientific Editor Work List	63631-Scientific editor work list.pdf